La Siddhi Consultancy v Athena Pharmaceutiques (CFI, 13 March 2026)
| Date | 13 March 2026 |
|---|---|
| Court | CFI |
| Division | Milan (IT) Central Division- Section |
| Type of action | Revocation Action |
| Case number(s) | UPC_CFI_927/2025 |
| Registry reference | UPC-CFI-0000927/2025 |
| Parties | La Siddhi Consultancy Limited v. Athena Pharmaceutiques SAS, Substipharm |
Official decision (PDF) · UPC registry entry
Case timeline
- 19 May 2026 : La Siddhi Consultancy v Athena Pharmaceutiques (CFI, 19 May 2026) UPC-CFI-0000927/2025
Dhenne Avocats represents claimants and defendants in European patent disputes before the Unified Patent Court, including the Paris divisions.
Dhenne Avocats · 10 October 2026
Our analysis
Summary
By an order of 13 March 2026 (UPC_CFI_927/2025), the Milan Central Division, ordered La Siddhi Consultancy, the UK claimant in the revocation action against unitary patent EP 3 592 333, to provide within six weeks security of EUR 75,000 for the costs of Athena Pharmaceutiques and Substipharm, which had sought EUR 112,000. The order shows that security follows an estimate of first-instance costs rather than the ceiling, and that SME status must be shown with figures.
Question
Does the claimant’s financial position justify security for costs under Rule 158 RoP, in what amount and within what time, and does its SME status warrant a reduction?
Decision
The test is whether there is a legitimate and real concern that a costs order may not be recovered, in light of the claimant’s own position. The group’s position is irrelevant absent a guarantee (paragraph 14). The undisputed 2024 balance sheet leaves a margin of about EUR 31,000 between current assets and current liabilities, and the claimant showed no improvement (paragraphs 20 to 24). For a value in dispute of EUR 1 million the ceiling is EUR 112,000, but the Division set EUR 75,000 in the absence of a costs estimate, excluding appeal costs (paragraphs 25 to 28). The declaration filed gave no figures on headcount, turnover or balance sheet, so micro-enterprise status was not established (paragraph 29). Six weeks is a reasonable time limit (paragraph 31), and leave to appeal was granted.
Key points for practice
- The ceiling on recoverable costs is not the default amount of security: absent an estimate, the Division sets a lower figure itself.
- Practical point: a claimant relying on SME status to reduce security must produce its headcount, turnover and balance sheet.
Provisions applied
- Agreement on a Unified Patent Court
- Art. 69(1) and (4) and 73
- Rules of Procedure
- Rules 158.1, 158.4, 158.5, 171.2, 220.2, 224.1(b), 355 and 370.8
- Other texts
- Commission Recommendation 2003/361/EC, Annex, Art. 2(3)
- Case law cited
- Syntorr v Arthrex, Court of Appeal, 18 February 2026, Chint v JingAo, Court of Appeal, 9 July 2025, Audi v NST, Court of Appeal, 17 September 2024, Suinno v Microsoft, Court of Appeal, 12 July 2025, Aarke v SodaStream, Court of Appeal, 29 November 2024, Visibly v Easee, Hamburg Local Division, 30 May 2025, BfexaQC v NVIDIA, Munich Local Division, 28 October 2025 (UPC_CFI_729/2025)
Prepared by Dhenne Avocats from the official decision, consulted on 10 October 2026. The database is updated every week, on Friday. Only the official text is authoritative.
Decisions in the same proceedings
Going further
Lexicon: Revocation action.
Publications by Matthieu Dhenne: G 1/25, Take Three: Anything You Leave in the Description May Be Used Against You (Kluwer Patent Blog).
Source and translations
- Official source
- Unified Patent Court registry link recorded in the record
- Original language
- not recorded
- Translation available
- no translation recorded the firm’s French record is a summary, not a translation
- Date checked
- not recorded
Follow this case
Proceedings, related decisions, appeals, parties and patents as recorded in the registry and in the Dhenne Avocats corpus. Each link states its source.
Parties
- claimantLa Siddhi Consultancy Limited4 decisions in the corpusFollow this party
- defendantAthena Pharmaceutiques SAS4 decisions in the corpusFollow this party
- defendantSubstipharm4 decisions in the corpusFollow this party
Decisions in the same proceedings and documented appeals
- 13 March 2026 La Siddhi Consultancy v Athena Pharmaceutiques (CFI, 13 March 2026) Revocation Action · UPC_CFI_927/2025
- 19 May 2026 La Siddhi Consultancy v Athena Pharmaceutiques (CFI, 19 May 2026) Revocation Action · UPC_CFI_927/2025
Le régime « external eyes only » demandé pour un accord produit au soutien de la qualité à agir est refusé. L'accès est ouvert, côté défenderesses, aux représentants externes, à leur directeur juridique et à un conseil indien.
What the record states
- Nature of the act
- Revocation Action
- Outcome (Dhenne Avocats summary)
- La Siddhi Consultancy doit fournir sous six semaines une garantie de 75 000 euros pour les frais des défenderesses, sa situation financière faisant craindre un défaut de recouvrement et son statut de PME n'étant pas établi. L'autorisation d'appel est accordée.
- Appeal
- No appeal documented in the corpus, this does not mean that no appeal was lodged.
- Instance
- First-instance decision, whether it has become final is not recorded.
Patents mentioned
EP 3 592 333mentioned in: Dhenne Avocats analysis Follow this patent
Related decisions cited in the analyses
- La Siddhi Consultancy v Athena Pharmaceutiques (CFI, 19 May 2026) cited in this record
- Syntorr LP v Arthrex (CoA, UPC_CoA_890/2025, 18 February 2026) cited in this record
- Suinno Mobile & AI Licensing v Microsoft (CoA, 12 July 2025) cited in this record
- Chint New Energy v JingAo Solar (CoA, 9 July 2025) cited in this record
- Visibly v Easee (CFI, 30 May 2025) cited in this record
- Aarke v SodaStream Industries (CoA, 29 November 2024) cited in this record
- Audi v Network System Technologies (CoA, 17 September 2024) cited in this record
- La Siddhi Consultancy v Athena Pharmaceutiques (CoA, 1 June 2026) cites this decision
- La Siddhi Consultancy v Athena Pharmaceutiques (CoA, 14 April 2026) cites this decision
Patents and standards
| Publication | Role in the dispute | Family | Standard and declaration | Pool | Sources |
|---|---|---|---|---|---|
EP 3 592 333 | Mentioned in the analysis (role not qualified) Also mentioned in 3 other decision(s): La Siddhi Consultancy v Athena Pharmaceutiques (CoA, 1 June 2026) · La Siddhi Consultancy v Athena Pharmaceutiques (CFI, 19 May 2026) · La Siddhi Consultancy v Athena Pharmaceutiques (CoA, 14 April 2026) | not recorded | not recorded | not recorded | Espacenet links not checked mentioned in: Dhenne Avocats analysis |
Receive an alert
Weekly summary of new records and substantive updates matching what you follow. Address confirmed by email, unsubscribe at any time, one email per week even where several of your follows match.